VR Adviser, LLC
- SEC CIK
- 0001615982
- Latest filing
- Aug 14, 2026
Holdings in Q1 2025
Holdings as of Mar 31, 2025, filed May 15, 2025. Long positions only; changes compare share counts with Q4 2024.
- Positions
- 37
- 0 vs. Q4 2024
- Portfolio value
- $1.18B
- −$282.2M (−19.4%) vs. Q4 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| APGEApogee Therapeutics, Inc. | COM | 8,493,321 | $317.3M | 27.0% | 00.0% | Unchanged | History |
| MTSRMetsera, Inc. | COM | 3,750,662 | $102.1M | 8.7% | +3,750,662 | New | History |
| OCULOcular Therapeutix, Inc | COM | 12,762,462 | $93.5M | 8.0% | 00.0% | Unchanged | History |
| ELVNEnliven Therapeutics, Inc. | COM | 4,026,331 | $79.2M | 6.7% | 00.0% | Unchanged | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 6,703,985 | $77.4M | 6.6% | +454,254+7.3% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 3,882,709 | $52.3M | 4.5% | 00.0% | Unchanged | History |
| PHVSPharvaris N.V. | COM | 3,112,720 | $48.9M | 4.2% | −107,410−3.3% | Reduced | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 2,685,448 | $43.3M | 3.7% | 00.0% | Unchanged | History |
| ORKAOruka Therapeutics, Inc. | COM | 4,148,428 | $42.6M | 3.6% | +862,808+26.3% | Added | History |
| PRAXPraxis Precision Medicines, Inc. | COM NEW | 989,985 | $37.5M | 3.2% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 5,684,411 | $34.0M | 2.9% | 00.0% | Unchanged | History |
| DNTHDianthus Therapeutics, Inc. | COM | 1,744,373 | $31.6M | 2.7% | 00.0% | Unchanged | History |
| DYNDyne Therapeutics, Inc. | COM | 2,173,913 | $22.7M | 1.9% | 00.0% | Unchanged | History |
| CDTXCidara Therapeutics, Inc. | COM NEW | 1,051,518 | $22.6M | 1.9% | +285,795+37.3% | Added | History |
| ENGNenGene Therapeutics Inc. | COM | 5,046,414 | $22.6M | 1.9% | 00.0% | Unchanged | History |
| ERASErasca, Inc. | COM | 16,216,216 | $22.2M | 1.9% | 00.0% | Unchanged | History |
| ORICOric Pharmaceuticals, Inc. | COM | 3,182,527 | $17.8M | 1.5% | −1,212,000−27.6% | Reduced | History |
| UPBUpstream Bio, Inc. | COM | 2,295,319 | $14.0M | 1.2% | 00.0% | Unchanged | History |
| ATXSAstria Therapeutics, Inc. | COM | 2,457,348 | $13.1M | 1.1% | 00.0% | Unchanged | History |
| CGEMCullinan Therapeutics, Inc. | COM | 1,379,965 | $10.4M | 0.9% | 00.0% | Unchanged | History |
| SLDBSolid Biosciences Inc. | COM NEW | 2,481,400 | $9.18M | 0.8% | +2,481,400 | New | History |
| SVRASavara Inc | COM | 3,257,639 | $9.02M | 0.8% | +3,257,639 | New | History |
| ABVXAbivax S.A. | SPONSORED ADS | 1,345,780 | $8.41M | 0.7% | 00.0% | Unchanged | History |
| FRNMFreenome, Inc. | CL A ORD SHS | 750,000 | $7.72M | 0.7% | 00.0% | Unchanged | History |
| SRZNSurrozen, Inc. | COM NEW | 632,931 | $7.38M | 0.6% | +632,931 | New | History |
| ZURAZura Bio Ltd | CLASS A ORD SHS | 5,023,166 | $6.48M | 0.6% | +3,000,000+148.3% | Added | History |
| ARTVArtiva Biotherapeutics, Inc. | COM | 1,609,569 | $4.83M | 0.4% | 00.0% | Unchanged | History |
| TRVITrevi Therapeutics, Inc. | COM | 615,506 | $3.87M | 0.3% | −650,951−51.4% | Reduced | History |
| APLTApplied Therapeutics, Inc. | COM | 5,567,709 | $2.72M | 0.2% | −4,422,882−44.3% | Reduced | History |
| FDMT4D Molecular Therapeutics, Inc. | COM | 677,600 | $2.19M | 0.2% | −2,274,771−77.0% | Reduced | History |
| CASIFCASI Pharmaceuticals, Inc. | ORD SHS | 987,259 | $2.13M | 0.2% | 00.0% | Unchanged | History |
| TENXTenax Therapeutics, Inc. | COM NEW | 208,333 | $1.36M | 0.1% | 00.0% | Unchanged | History |
| MRSNMersana Therapeutics, Inc. | COM | 3,574,325 | $1.23M | 0.1% | −6,683,465−65.2% | Reduced | History |
| IPSCCentury Therapeutics, Inc. | COM | 2,498,069 | $1.19M | 0.1% | −1,459,117−36.9% | Reduced | History |
| TNYATenaya Therapeutics, Inc. | COM | 1,555,556 | $886.8K | 0.1% | 00.0% | Unchanged | History |
| CBIOCrescent Biopharma, Inc. | COM | 3,000,000 | $630.0K | 0.1% | 00.0% | Unchanged | History |
| TILInstil Bio, Inc. | COM NEW | 33,177 | $576.0K | <0.1% | 00.0% | Unchanged | History |
Sold out since Q4 2024 (4)
Positions held at the end of Q4 2024 that are gone from this filing.
| Security | Class | Shares in Q4 2024 | Value in Q4 2024 | % of portfolio in Q4 2024 | History |
|---|---|---|---|---|---|
| MRUSMerus N.V. | COM | 592,411 | $24.9M | 1.7% | History |
| AQSTAquestive Therapeutics, Inc. | COM | 2,629,786 | $9.36M | 0.6% | History |
| TERNTerns Pharmaceuticals, Inc. | COM | 1,077,090 | $5.97M | 0.4% | History |
| TSHATaysha Gene Therapies, Inc. | COM SHS | 3,225,180 | $5.58M | 0.4% | History |